Terms: = Breast cancer AND CREBBP, CBP, 1387, ENSG00000005339, RSTS, RTS
294 results:
1. Novel berberine derivatives as p300 histone acetyltransferase inhibitors in combination treatment for breast cancer.
Lai R; Lin Z; Yang C; Hai L; Yang Z; Guo L; Nie R; Wu Y
Eur J Med Chem; 2024 Feb; 266():116116. PubMed ID: 38215590
[TBL] [Abstract] [Full Text] [Related]
2. Roles and signaling pathways of CITED1 in tumors: overview and novel insights.
Chen W; Jiang J; Gao J; Wang G; Wang R; Lv J; Ben J
J Int Med Res; 2024 Jan; 52(1):3000605231220890. PubMed ID: 38190845
[TBL] [Abstract] [Full Text] [Related]
3. Exploration of the Pharmacological Mechanism of Vitexicarpin against Triple-Negative breast cancer in Network Pharmacology.
Wu T; Xiang M; Li Y; Gao Y; Teng D; Sun M; Guo W; Zhou Y
Front Biosci (Landmark Ed); 2023 Dec; 28(12):341. PubMed ID: 38179762
[TBL] [Abstract] [Full Text] [Related]
4. Inhibition of CREB Binding and Function with a Dual-Targeting Ligand.
Liu Y; Joy ST; Henley MJ; Croskey A; Yates JA; Merajver SD; Mapp AK
Biochemistry; 2024 Jan; 63(1):1-8. PubMed ID: 38086054
[TBL] [Abstract] [Full Text] [Related]
5. The critical role of phlebolymphedema in cellulitis associated with lymphedema: Its incidence and economic impact in a large real-world population.
Tedesco A; O'Donnell T; Weycker D; Salehi P
J Vasc Surg Venous Lymphat Disord; 2024 Mar; 12(2):101704. PubMed ID: 37977518
[TBL] [Abstract] [Full Text] [Related]
6. I-cbp112 declines overexpression of ATP-binding cassette transporters and sensitized drug-resistant MDA-MB-231 and A549 cell lines to chemotherapy drugs.
Strachowska M; Gronkowska K; Sobczak M; Grodzicka M; Michlewska S; Kołacz K; Sarkar T; Korszun J; Ionov M; Robaszkiewicz A
Biomed Pharmacother; 2023 Dec; 168():115798. PubMed ID: 37913733
[TBL] [Abstract] [Full Text] [Related]
7. Clinicopathologic and mutational profiles of primary breast diffuse large B cell lymphoma in a male patient: case report and literature review.
Huang F; Ruan Y; He X; Lian H; Yang J
World J Surg Oncol; 2023 Oct; 21(1):342. PubMed ID: 37884941
[TBL] [Abstract] [Full Text] [Related]
8. Targeting c-Jun inhibits fatty acid oxidation to overcome tamoxifen resistance in estrogen receptor-positive breast cancer.
Jiang C; Zhu Y; Chen H; Lin J; Xie R; Li W; Xue J; Chen L; Chen X; Xu S
Cell Death Dis; 2023 Oct; 14(10):653. PubMed ID: 37803002
[TBL] [Abstract] [Full Text] [Related]
9. Solid-Basaloid Adenoid Cystic Carcinoma of the breast: An Aggressive Subtype Enriched for Notch Pathway and Chromatin Modifier Mutations With MYB Overexpression.
Shamir ER; Bean GR; Schwartz CJ; Vohra P; Wang A; Allard GM; Wolsky RJ; Garcia JJ; Chen YY; Krings G
Mod Pathol; 2023 Dec; 36(12):100324. PubMed ID: 37660928
[TBL] [Abstract] [Full Text] [Related]
10. Exposure to endogenous and exogenous sex hormones and reproductive history influence prognosis in women with ALS.
Gonzalez Deniselle MC; Bettini M; Garrido RM; Meyer M; Lara A; Garay LI; Casas S; Fulgenzi E; Nuñez M; Rugiero MF; De Nicola AF; Gargiulo-Monachelli G
Muscle Nerve; 2023 Oct; 68(4):414-421. PubMed ID: 37493444
[TBL] [Abstract] [Full Text] [Related]
11. ZNF451 favors triple-negative breast cancer progression by enhancing SLUG-mediated CCL5 transcriptional expression.
Zhang Y; Wang W; Min J; Liu S; Wang Q; Wang Y; Xiao Y; Li X; Zhou Z; Liu S
Cell Rep; 2023 Jun; 42(6):112654. PubMed ID: 37342906
[TBL] [Abstract] [Full Text] [Related]
12. Mutational signatures for breast cancer diagnosis using artificial intelligence.
Odhiambo P; Okello H; Wakaanya A; Wekesa C; Okoth P
J Egypt Natl Canc Inst; 2023 May; 35(1):14. PubMed ID: 37184779
[TBL] [Abstract] [Full Text] [Related]
13. Quality of Life in breast cancer Patients: A Systematic Review of the Qualitative Studies.
Heidary Z; Ghaemi M; Hossein Rashidi B; Kohandel Gargari O; Montazeri A
Cancer Control; 2023; 30():10732748231168318. PubMed ID: 37082898
[TBL] [Abstract] [Full Text] [Related]
14. Variable Landscape of PD-L1 Expression in breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay.
Danziger N; Sokol ES; Graf RP; Hiemenz MC; Maule J; Parimi V; Palmieri C; Pusztai L; Ross JS; Huang RSP
Oncologist; 2023 Apr; 28(4):319-326. PubMed ID: 36866462
[TBL] [Abstract] [Full Text] [Related]
15. FT-6876, a Potent and Selective Inhibitor of cbp/p300, is Active in Preclinical Models of Androgen Receptor-Positive breast cancer.
Caligiuri M; Williams GL; Castro J; Battalagine L; Wilker E; Yao L; Schiller S; Toms A; Li P; Pardo E; Graves B; Azofeifa J; Chicas A; Herbertz T; Lai M; Basken J; Wood KW; Xu Q; Guichard SM
Target Oncol; 2023 Mar; 18(2):269-285. PubMed ID: 36826464
[TBL] [Abstract] [Full Text] [Related]
16. Estrone, the major postmenopausal estrogen, binds ERa to induce SNAI2, epithelial-to-mesenchymal transition, and ER+ breast cancer metastasis.
Qureshi R; Picon-Ruiz M; Sho M; Van Booven D; Nunes de Paiva V; Diaz-Ruano AB; Ince TA; Slingerland J
Cell Rep; 2022 Nov; 41(7):111672. PubMed ID: 36384125
[TBL] [Abstract] [Full Text] [Related]
17. Au-TiO
Chaudhary VS; Kumar D; Kumar S
IEEE Trans Nanobioscience; 2023 Jul; 22(3):562-569. PubMed ID: 36327178
[TBL] [Abstract] [Full Text] [Related]
18. Bioinformatics analysis reveals the potential target of rosiglitazone as an antiangiogenic agent for breast cancer therapy.
Hermawan A; Putri H
BMC Genom Data; 2022 Sep; 23(1):72. PubMed ID: 36114448
[TBL] [Abstract] [Full Text] [Related]
19. Analysis of estrogen-regulated enhancer RNAs identifies a functional motif required for enhancer assembly and gene expression.
Hou TY; Kraus WL
Cell Rep; 2022 Jun; 39(11):110944. PubMed ID: 35705040
[TBL] [Abstract] [Full Text] [Related]
20. Transcriptional Repression by FoxM1 Suppresses Tumor Differentiation and Promotes Metastasis of breast cancer.
Kopanja D; Chand V; O'Brien E; Mukhopadhyay NK; Zappia MP; Islam ABMMK; Frolov MV; Merrill BJ; Raychaudhuri P
Cancer Res; 2022 Jul; 82(13):2458-2471. PubMed ID: 35583996
[TBL] [Abstract] [Full Text] [Related]
[Next]
